A running page from GoodRx following how insurers are handling coverage for GIP and GLP-1 drugs this year.
Recap by typeshit. Full story at GoodRx.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
Chemistry World reports Novo is buying rights to new weight loss and cardiometabolic drugs to offset expected revenue loss as semaglutide patents expire in Europe and the US.
The stock analysis puts Novo's P/E well under the 21.7x pharma average and asks whether recent semaglutide data justify a higher price.
Loading…